Description: Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of cancer immunotherapy drugs. The company offers Gene Mediated Cytotoxic Immunotherapy technology-based drugs that are designed to work with radiation, chemotherapy, and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. Its product candidates include CAN-2409, an off-the-shelf adenovirus product candidate, for the treatment of localized, primary prostate cancer and therapy for pancreatic cancer; and CAN-3110, its HSV product candidate, has been engineered for enhanced specificity and tumor cell killing, while minimizing toxicity on healthy tissue and indicated for the treatment of recurrent high-grade glioma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was founded in 1999 and is based in Needham, Massachusetts.
Home Page: www.candeltx.com
CADL Technical Analysis
117 Kendrick Street
Needham,
MA
02494
United States
Phone:
617 916 5445
Officers
| Name | Title |
|---|---|
| Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D. | Pres, CEO & Director |
| Dr. Estuardo Aguilar-Cordova Inf., M.D., Ph.D. | Founder & Director |
| Ms. Carrie Smith Cox | Special Advisor to the CEO |
| Mr. Jason A. Amello | Chief Financial Officer |
| Dr. Seshu Tyagarajan Ph.D. | Chief Technical & Devel. Officer |
| Dr. Francesca Barone M.D., Ph.D. | Chief Scientific Officer |
| Ms. Ileen B. Winick | Chief People Officer |
| Ms. Susan Stewart J.D., L.L.M. | Chief Regulatory Officer |
| Mr. Nathan Caffo | Chief Bus. Officer |
| Dr. William Garrett Nichols M.D., M.S., MS | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 66 |
| Price-to-Book MRQ: | 1.1585 |
| Price-to-Sales TTM: | 436.8773 |
| IPO Date: | 2021-07-27 |
| Fiscal Year End: | December |
| Full Time Employees: | 65 |